Deutsch
 
Benutzerhandbuch Datenschutzhinweis Impressum Kontakt
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Poster

Synthesis of High Affinity Contrast Agents for Targeted MR Neuroimaging

MPG-Autoren
/persons/resource/persons192632

Gündüz,  Serhat
Max Planck Institute for Biological Cybernetics, Max Planck Society;
Department Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons84656

Power,  AT
Max Planck Institute for Biological Cybernetics, Max Planck Society;
Department Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons84063

Logothetis,  Nikos K
Max Planck Institute for Biological Cybernetics, Max Planck Society;
Department Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons83784

Angelovski,  Goran
Max Planck Institute for Biological Cybernetics, Max Planck Society;
Department Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, Max Planck Society;

Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Gündüz, S., Power, A., Logothetis, N. K., & Angelovski, G. (2013). Synthesis of High Affinity Contrast Agents for Targeted MR Neuroimaging. Poster presented at COST TD1004 Action: Theranostics Imaging and Therapy: An Action to Develop Novel Nanosized Systems for Imaging: Guided Drug Delivery, Athens, Greece.


Zitierlink: http://hdl.handle.net/21.11116/0000-0000-FE75-F
Zusammenfassung
Magnetic resonance imaging (MRI) has become one of the essential noninvasive diagnostic techniques for soft tissues and diseases. Contrast agents have been developed to produce additional contrast and increase the signal intensity for MRI [1]. Here we report on the synthesis development of target specific contrast agents for MR neuroimaging. Monomeric and dendrimeric targeted contrast agents (TCA) were synthesized taking advantage of the highly specific interaction of the protein avidin with its ligand biotin [2]. The classical monomeric CAs have disadvantages such as non-specificity, fast renal excretion, low contrast efficiency and therefore they require a high dosage. To overcome this problem, we use multivalent, highly-branched dendrimeric molecules that are capable of carrying large number of CAs and hence the MRI amplification [3]. The TCAs are additionally labeled with a fluorescent dye, for to achieve their multimodal detection by means of optical and MR-based techniques. Upon their preparation, the biotinylated TCAs are suitable for labeling genetically engineered cell surface receptors that contain avidin. [4]. The preliminary experiments showed that TCAs bind specifically to avidin-coated beads (Figure 1). Their further characterization ensures exciting progress in neuroimaging enabling high resolution MRI of specific neuronal populations.